At the sharp end

Article

Hoya Surgical Products now has, what it claims to be, the Sharpest Edge on the market. The yellow aspheric blue-light filter IOLS iSymm has undergone a unique manufacturing process which makes it the sharpest of all commercially available IOLs currently in the market.

Hoya Surgical Products now has, what it claims to be, the Sharpest Edge on the market. The yellow aspheric blue-light filter IOLS iSymm has undergone a unique manufacturing process which makes it the sharpest of all commercially available IOLs currently in the market.

Professors Liliana Werner and Manfred Tetz have been studying the edge profiles of currently available IOLs and their recent improvements and their research is to be published in the European Opthalmic Review (Vol 3 Issue 2). Its conclusions are that their analysis revealed “a large variation of deviation from a perfect square, as well as mean values that were higher for hydrophilic acrylic lenses in comparison with values reported for hydrophobic acrylic and silicone lenses. Only existing and future clinical data will help us better understand the effect of microedge structure and design on reducing posterior capsule opacification (PCO), but perhaps a cut-off value to clinically label an IOL as square-edged should be sought. The methodology used in such studies can help optimise the edge profile of IOLS.”

Another positive announcement from the company is that HOYA received the FDA Approval for the iSert preloaded implantation system in the USA. “This big step allows HOYA Surgical Optics now to introduce the first and only preloaded intraocular lens injection system in the US,” said Hoya's head of marketing, Mike Galloway.

Galloway also confirmed that HOYA Surgical Optics will provide ophthalmologists with advanced products and professional services with plenty of ideas in the pipeline.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.